Brixton Biosciences

About Brixton Biosciences

Brixton Biosciences aims to disrupt pain and empower movement by providing innovative solutions for long-lasting pain control, with a focus on transforming pain management through their product Neural Ice™.

Products & Services

Neural Ice™:A pain management solution developed at Massachusetts General Hospital, offering potential relief for 3 months or more from a single treatment, with applications for both acute and chronic pain.

Specialties

Pain Management Neural Technology Clinical Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2024-10-24 FD: 2024-10-24	1 investors
2	RT: Series B T: - FT: Series B	A: 33000000 MR: - FA: $33M FAN: 33000000	D: 2024-05-14 FD: 2024-05-14	6 investors

Grant Latest

2024-10-24

$2.0M

1 investor (Pro only)

Series B 2024-05-14

$33.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

R. Rox Anderson

Professor

S

Sameer Sabir

CEO

L

Lilit Garibyan

Associate Professor

C

Charles Sidoti

Chief Technology Officer

M

Michael Fishman

Chief Medical Officer

B

Ben de la Cretaz

Chief Financial Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News